Table 2.

Responses of CNS and systemic disease at different timepoints of protocol treatment

	Whole series (n=75)	CNS disease (n=75)	Systemic disease (n=60)	CNS disease at presentation (n=32)	Relapse; isolated CNS disease (n=15)	Relapse; CNS–systemic disease (n=28)
After second MATRix*
Complete response	20 (27%)	26 (35%)	26 (43%)	11 (34%)	4 (27%)	5 (18%)
Partial response	36 (48%)	31 (41%)	19 (32%)	17 (53%)	6 (40%)	13 (46%)
Objective response	56 (75%)	57 (76%)	45 (75%)	28 (88%)	10 (67%)	18 (64%)
Stable disease	3 (4%)	6 (8%)	3 (5%)	1 (3%)	1 (7%)	1 (4%)
Progressive disease	12 (16%)	8 (11%)	10 (17%)	3 (9%)	2 (13%)	7 (25%)
After MATRix–RICE
Complete response	29 (39%)	37 (49%)	33 (55%)	17 (53%)	6 (40%)	6 (21%)
Partial response	20 (27%)	14 (19%)	12 (20%)	10 (31%)	3 (20%)	7 (25%)
Objective response	49 (65%)	51 (68%)	45 (75%)	27 (84%)	9 (60%)	13 (46%)
Stable disease	0	0	0	0	0	0
Progressive disease	22 (29%)	20 (27%)	13 (22%)	5 (16%)	4 (27%)	13 (46%)
Whole treatment
Complete response	41 (55%)	44 (59%)	40 (67%)	24 (75%)	7 (47%)	9 (32%)
Partial response	5 (7%)	2 (3%)	4 (7%)	2 (6%)	0	3 (11%)
Objective response	46 (61%)	46 (61%)	44 (73%)	26 (81%)	7 (47%)	12 (43%)
Stable disease	0	0	0	0	0	0
Progressive disease	25 (33%)	25 (33%)	14 (23%)	6 (19%)	6 (40%)	14 (50%)

Data are n (%). Whole series column shows all responses in all patients, CNS disease column shows responses related only to CNS disease (all patients); and systemic disease column shows responses only related to extra-CNS disease in patients who had extra-CNS disease. MATRix=methotrexate, cytarabine, thiotepa, and rituximab. RICE=rituximab, ifosfamide, carboplatin, and etoposide.

^*Four patients died of toxicity during MATRix; two of them had concomitant systemic disease.